Literature DB >> 26079411

The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B.

Patrick J Lao1, Tobey J Betthauser1, Ansel T Hillmer1, Julie C Price2, William E Klunk3, Iulia Mihaila4, Andrew T Higgins4, Peter D Bulova2, Sigan L Hartley4, Regina Hardison5, Rameshwari V Tumuluru3, Dhanabalan Murali1, Chester A Mathis6, Annie D Cohen3, Todd E Barnhart7, Darlynne A Devenny8, Marsha R Mailick4, Sterling C Johnson9, Benjamin L Handen3, Bradley T Christian10.   

Abstract

INTRODUCTION: In Down syndrome (DS), the overproduction of amyloid precursor protein is hypothesized to predispose young adults to early expression of Alzheimer-like neuropathology.
METHODS: PET imaging with carbon 11-labeled Pittsburgh compound B examined the pattern of amyloid-β deposition in 68 nondemented adults with DS (30-53 years) to determine the relationship between deposition and normal aging. Standard uptake value ratio (SUVR) images were created with cerebellar gray matter as the reference region.
RESULTS: Multiple linear regression revealed slight but highly significant (corrected P < .05) positive correlations between SUVR and age. The striatum showed the strongest correlation, followed by precuneus, parietal cortex, anterior cingulate, frontal cortex, and temporal cortex.
CONCLUSION: There is an age-related amyloid-β deposition in the DS population, but as a pattern of elevated cortical retention becomes apparent, the correlation of SUVR with age ceases to be significant. Factors unrelated to aging may drive an increase in deposition during early Alzheimer's disease pathogenesis.
Copyright © 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Alzheimer's disease; Amyloid imaging; Down syndrome; PiB

Mesh:

Substances:

Year:  2015        PMID: 26079411      PMCID: PMC4677061          DOI: 10.1016/j.jalz.2015.05.013

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  34 in total

Review 1.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

2.  PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease.

Authors:  J Koivunen; A Verkkoniemi; S Aalto; A Paetau; J-P Ahonen; M Viitanen; K Någren; J Rokka; M Haaparanta; H Kalimo; J O Rinne
Journal:  Brain       Date:  2008-06-25       Impact factor: 13.501

3.  Presenile dementia and Alzheimer's disease in mongolism.

Authors:  M I Olson; C M Shaw
Journal:  Brain       Date:  1969-03       Impact factor: 13.501

4.  The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease.

Authors:  R Mayeux; Y Stern; R Ottman; T K Tatemichi; M X Tang; G Maestre; C Ngai; B Tycko; H Ginsberg
Journal:  Ann Neurol       Date:  1993-11       Impact factor: 10.422

5.  Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.

Authors:  B Rumble; R Retallack; C Hilbich; G Simms; G Multhaup; R Martins; A Hockey; P Montgomery; K Beyreuther; C L Masters
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

6.  Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.

Authors:  Rebecca L McNamee; Seong-Hwan Yee; Julie C Price; William E Klunk; Bedda Rosario; Lisa Weissfeld; Scott Ziolko; Michael Berginc; Brian Lopresti; Steven Dekosky; Chester A Mathis
Journal:  J Nucl Med       Date:  2009-02-17       Impact factor: 10.057

7.  Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.

Authors:  William E Klunk; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Brian J Lopresti; Scott K Ziolko; Wenzhu Bi; Jessica A Hoge; Ann D Cohen; Milos D Ikonomovic; Judith A Saxton; Beth E Snitz; Daniel A Pollen; Majaz Moonis; Carol F Lippa; Joan M Swearer; Keith A Johnson; Dorene M Rentz; Alan J Fischman; Howard J Aizenstein; Steven T DeKosky
Journal:  J Neurosci       Date:  2007-06-06       Impact factor: 6.167

8.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

9.  Frequent amyloid deposition without significant cognitive impairment among the elderly.

Authors:  Howard Jay Aizenstein; Robert D Nebes; Judith A Saxton; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Scott K Ziolko; Jeffrey A James; Beth E Snitz; Patricia R Houck; Wenzhu Bi; Ann D Cohen; Brian J Lopresti; Steven T DeKosky; Edythe M Halligan; William E Klunk
Journal:  Arch Neurol       Date:  2008-11

Review 10.  Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease.

Authors:  Gaël Chételat; Renaud La Joie; Nicolas Villain; Audrey Perrotin; Vincent de La Sayette; Francis Eustache; Rik Vandenberghe
Journal:  Neuroimage Clin       Date:  2013-03-05       Impact factor: 4.881

View more
  42 in total

1.  Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.

Authors:  Sigan L Hartley; Benjamin L Handen; Darlynne Devenny; Iulia Mihaila; Regina Hardison; Patrick J Lao; William E Klunk; Peter Bulova; Sterling C Johnson; Bradley T Christian
Journal:  Neurobiol Aging       Date:  2017-06-02       Impact factor: 4.673

Review 2.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

3.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

4.  Alzheimer-Related Cerebrovascular Disease in Down Syndrome.

Authors:  Patrick J Lao; José Gutierrez; David Keator; Batool Rizvi; Arit Banerjee; Kay C Igwe; Krystal K Laing; Mithra Sathishkumar; Fahmida Moni; Howard Andrews; Sharon Krinsky-McHale; Elizabeth Head; Joseph H Lee; Florence Lai; Michael A Yassa; H Diana Rosas; Wayne Silverman; Ira T Lott; Nicole Schupf; Adam M Brickman
Journal:  Ann Neurol       Date:  2020-10-09       Impact factor: 10.422

5.  Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.

Authors:  Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 6.  Intellectual and developmental disabilities research centers: Fifty years of scientific accomplishments.

Authors:  Steven U Walkley; Leonard Abbeduto; Mark L Batshaw; Anita Bhattacharyya; Susan Y Bookheimer; Bradley T Christian; John N Constantino; Jean de Vellis; Daniel A Doherty; David L Nelson; Joseph Piven; Annapurna Poduri; Scott L Pomeroy; Rodney C Samaco; Huda Y Zoghbi; Michael J Guralnick
Journal:  Ann Neurol       Date:  2019-07-27       Impact factor: 10.422

Review 7.  Small-molecule PET Tracers for Imaging Proteinopathies.

Authors:  Chester A Mathis; Brian J Lopresti; Milos D Ikonomovic; William E Klunk
Journal:  Semin Nucl Med       Date:  2017-07-13       Impact factor: 4.446

8.  Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome.

Authors:  Patrick J Lao; Ben L Handen; Tobey J Betthauser; Iulia Mihaila; Sigan L Hartley; Annie D Cohen; Dana L Tudorascu; Peter D Bulova; Brian J Lopresti; Rameshwari V Tumuluru; Dhanabalan Murali; Chester A Mathis; Todd E Barnhart; Charles K Stone; Julie C Price; Darlynne A Devenny; Sterling C Johnson; William E Klunk; Bradley T Christian
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

9.  Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

10.  Comparison of longitudinal Aβ in nondemented elderly and Down syndrome.

Authors:  Dana L Tudorascu; Stewart J Anderson; Davneet S Minhas; Zheming Yu; Diane Comer; Patrick Lao; Sigan Hartley; Charles M Laymon; Beth E Snitz; Brian J Lopresti; Sterling Johnson; Julie C Price; Chester A Mathis; Howard J Aizenstein; William E Klunk; Benjamin L Handen; Brad T Christian; Ann D Cohen
Journal:  Neurobiol Aging       Date:  2018-09-27       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.